Sermorelin 9mg (2.5 mg/mL)
Sermorelin 9mg (2.5 mg/mL) is used in prescriber-directed longevity, peptide, antioxidant, or skin-longevity protocols. Published evidence varies substantially by ingredient, so the page avoids unsupported disease-treatment claims.
Sermorelin 9 mg at a concentration of 2.5 mg/mL (3.6 mL total volume) is a compounded multi-dose injectable preparation of the synthetic GHRH(1-29) analog sermorelin, identical in pharmacological mechanism to the 15 mg vial (ID 186) but in a smaller total volume suited for shorter treatment courses or lower-frequency dosing regimens. The pharmacodynamics, clinical use, safety profile, and monitoring requirements are identical to sermorelin 15 mg/2.5 mg/mL. Genesis Compounding prepares this as a prescription-only 503A compounded preparation that is not FDA-approved in this formulation.
| Active Ingredient | Pharmacologic Role |
|---|---|
| Sermorelin Acetate 2.5 mg/mL (9 mg total per vial) | Synthetic GHRH(1-29) analog that activates pituitary GHRH receptors to stimulate pulsatile endogenous growth hormone secretion. |
Identical to sermorelin 15 mg (ID 186). Subcutaneous injection at bedtime on an empty stomach; rotate injection sites; use insulin syringe for precise volume measurement.
Prescriber-determined. At 2.5 mg/mL in a 3.6 mL vial, common doses of 200–500 mcg (0.08–0.2 mL) yield approximately 18–45 doses per vial. This smaller vial size may be appropriate for a 2–3 month treatment cycle at standard doses, or for patients on less frequent protocols. All dose decisions rest with the prescribing clinician.
- Sermorelin: Identical mechanism to ID 186—GHRH receptor agonism on anterior pituitary somatotroph cells with cAMP-mediated GH gene transcription and pulsatile GH secretion, with somatostatin feedback loop preservation.
Identical clinical context, indications, and monitoring requirements to sermorelin 15 mg (ID 186). The 9 mg vial is a quantity difference only.
Identical safety profile, contraindications, warnings, and drug interactions to sermorelin 15 mg (ID 186). See that entry for complete safety information.
Store refrigerated (2–8°C). Do not freeze. Protect from light. Use within beyond-use date assigned by Genesis Compounding. Swirl gently if mixing is needed; do not shake vigorously. Keep out of reach of children.
How does this 9 mg vial differ from the 15 mg vial?
The concentration (2.5 mg/mL) and active ingredient are identical. The 9 mg vial contains a smaller total amount of sermorelin (3.6 mL versus 6 mL), providing fewer total doses. Your prescriber has selected this quantity based on your treatment duration and dose.
Will the effects be the same?
Yes—pharmacodynamics are determined by the dose administered (in mcg or mg per injection), not by the total vial size. As long as the prescribed dose and administration instructions are followed, the clinical effects are the same as with the larger vial.
When should I contact my prescriber about refills?
Based on your prescribed weekly dose, calculate how many doses are in the vial. Contact your prescriber for assessment and refill authorization at least 1–2 weeks before the vial is expected to run out, allowing time for laboratory monitoring and follow-up as part of the treatment protocol.
Is this FDA-approved?
Sermorelin as a compounded preparation is not FDA-approved. Sermorelin was previously FDA-approved (Geref) for pediatric GH deficiency diagnosis/treatment but is no longer commercially manufactured. This 503A compounded preparation from Genesis Compounding is prepared under a valid prescriber order.
Clinical References
Authoritative sources reviewed in preparing this clinical summary. Provided for prescriber reference; not a substitute for the prescriber’s clinical judgment.